Despite growing commercial interest in antimicrobial strategies that rely on antibodies, recent clinical trial failures suggest they are a work in progress.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Eash, S. Pharmacor, Infectious Disease, Study #2 2006 Decision Resources, Waltham, MA (2006) in press.
Projan, S.J., Nesin, M. & Dunman, P.M. Curr. Opin. Pharmacol. 6, 473–479 (2006).
Pirofski, L.A. & Casadevall, A. Curr. Opin. Microbiol. 9, 489–495 (2006).
Casadevall, A. Clin. Infect. Dis. 42, 1414–1416 (2006).
Rights and permissions
About this article
Cite this article
Baker, M. Anti-infective antibodies: finding the path forward. Nat Biotechnol 24, 1491–1493 (2006). https://doi.org/10.1038/nbt1206-1491
This article is cited by
Anti-infective monoclonals step in where antimicrobials fail
Nature Biotechnology (2013)
The contribution of immunology to the rational design of novel antibacterial vaccines
Nature Reviews Microbiology (2007)